Abstracts tagged "gout"

Abstract Number: 1043 • ACR Convergence 2025
The Care Pathway and Treatment Patterns in Patients with Uncontrolled Gout: A Real-World Survey of Physicians In The United States
Gordon Lam¹, Menaka Bhor², James Hawthorne², Arinola Dada³, Molly Edwards⁴, Emily Goddard⁴ and John Albert⁵, ¹Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²Sobi Inc, Waltham, MA, ³Overlake Arthritis and Osteoporosis Center, Bellevue, WA, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Rheumatic Disease Center, Glendale, WI
Background/Purpose: Uncontrolled gout (UG) is a chronic, progressive, and systemic disease characterized by serum uric acid (sUA) >6 mg/dl and clinical manifestations such as tophi,…
Abstract Number: 2585 • ACR Convergence 2025
The effect of prophylactic colchicine use on gene expression in gout
Austin Wheeler¹, Guanqi Lu², Ana Vazquez³, Jeffrey Edberg⁴, Angelo Gaffo⁵, Tate Johnson¹, Michael Duryee¹, James O'Dell¹, Jeff Newcomb¹, Michael Pillinger⁶, Robert Terkeltaub⁷, Ryan Ferguson⁸, Mary Brophy⁸, Tuhina Neogi⁹, Bryant England¹, Ted Mikuls¹, Tony Merriman¹⁰ and Richard Reynolds⁴, ¹University of Nebraska Medical Center, Omaha, NE, ²Michigan State University, East Lansing, MI, ³Michigan State University, Miami, FL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ⁶New York University Grossman School of Medicine, New York,, NY, ⁷Retired, San Diego, CA, ⁸VA Cooperative Studies Program Coordinating Center, Boston, MA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Colchicine is recommended for the treatment and prophylaxis of gout flares and approved for secondary prevention of ischemic cardiovascular disease (CVD). While its primary…
Abstract Number: 1998 • ACR Convergence 2025
Reduction in Tophi Observed in Patients with Uncontrolled Gout Treated with NASP: Results from Phase 3 DISSOLVE Studies
Herbert Baraf¹, Puja Khanna², Frédéric Lioté³, Rehan Azeem⁴, Wesley DeHaan⁵, Ben Peace⁶, Hugues Santin-Janin⁷, Bhavisha Desai⁸ and Alan Kivitz⁹, ¹The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Université Paris Cité-Inserm UMR¹¹³² & Rheumatology Department, GH Paris Saint Joseph & Institut Arthur Vernes, Paris, France, ⁴Global MACD, Sobi Inc., Waltham, MA, ⁵Sobi, Inc, Waltham, MA, ⁶Statistical Science, Sobi, Stockholm, Sweden, ⁷Sobi, BASEL, Switzerland, ⁸Sobi, Glastonbury, CT, ⁹Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Patients (pts) with uncontrolled gout (UG) and tophi experience joint pain, impaired function and poor quality of life (Schlesinger et al. Semin Arthritis Rheum…
Abstract Number: 1145 • ACR Convergence 2025
Numerically Reduced but MSU Crystal-Activated NK Cells Promote Osteoclastogenesis in Gout
Ki-Jeong Park¹, Young-Nan Cho², Hye-Mi Jin², Hye-Min Jeong², Sung-Eun Choi³, Ji-Hyoun Kang¹, Dong-Jin Park¹, Tae-jong Kim⁴, Shin-Seok Lee⁵ and Yong-Wook Park⁶, ¹Chonnam National University Hospital, Gwangju, Republic of Korea, ²Chonnam National University Medical School, Gwangju, Republic of Korea, ³Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea, ⁴Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwang-Ju, South Korea, ⁵Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, ⁶Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea
Background/Purpose: Gout is an inflammatory arthritis characterized by acute attacks, tophi formation, and bone destruction triggered by inflammatory responses to monosodium urate (MSU) crystals. Natural…
Abstract Number: 1032 • ACR Convergence 2025
Exploring the role of the gut microbiome in gout: Prospective analysis of dietary fiber intake and the risk of gout
Sharan Rai¹, Natalie McCormick², Chio Yokose³, Robert Terkeltaub⁴, Dylan Dodd⁵, Lama Nazzal⁶, Huilin Li⁶, Qi Sun⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital/Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Waltham, MA, ⁴Retired, San Diego, CA, ⁵Stanford University, Palo Alto, CA, ⁶NYU Langone, New York, NY, ⁷Harvard T.H. Chan School of Public Health, Boston, ⁸MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: The role of the gut microbiome has been increasingly implicated in the pathogenesis of gout. For instance, gout patients have shown depletions of bacteria…
Abstract Number: 2548 • ACR Convergence 2025
Management of Uncontrolled Gout Among Rheumatologists: Findings from a Medical Chart Audit
Hyon K. Choi¹, Nana Kragh², Amod Athavale³, Bhavisha Desai⁴, Amal Gulaid³, Abiola Oladapo⁵, Brittany Smith³ and Kenneth Saag⁶, ¹MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ²Sobi, Kongens Lyngby, Denmark, ³Trinity Life Sciences, Waltham, MA, ⁴Sobi, Glastonbury, CT, ⁵Sobi INC, Waltham, MA, ⁶The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Uncontrolled gout (UG) is defined by persistently high sUA levels, despite the use of oral urate lowering treatments (ULT), resulting in gout-related manifestations. Current…
Abstract Number: 1997 • ACR Convergence 2025
Bone health in patients with gout using real-world U.S. data
Emily Holladay¹, Alexis Woods², Fenglong Xie³, Jingyi Zhang¹, Angelo Gaffo⁴, Jeffrey Curtis⁵ and Brian Lamoreaux⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Amgen, Detroit, MI, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁶Amgen, Inc., Deerfield, IL
Background/Purpose: Patients with gout may be at high risk for developing osteoporosis and fractures, but osteoporosis may be under-recognized and inadequately managed for gout patients.…
Abstract Number: 1143 • ACR Convergence 2025
Gout and Renal Failure-Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database
Shiamak Cooper¹, Sanjana Thimmannagari², Ranjini Vengilote² and Asim Khanfar², ¹Rochester General Hospital, Irondequoit, NY, ²Rochester General Hospital, Rochester, NY
Background/Purpose: Gout is the most common form of inflammatory arthropathy, with a prevalence ranging from 0.1% to approximately 10% worldwide. Despite a well-established association between…
Abstract Number: 1026 • ACR Convergence 2025
Seasonal Variation in Public Interest in Gout Made More Crystal-Clear: A Longitudinal Infodemiology Study Using Google Trends.
Naomi Schlesinger¹ and Ioannis Androulakis², ¹Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT, ²Rutgers University, Piscataway, NJ
Background/Purpose: Understanding public interest in gout, as reflected by online behavior, can offer valuable insights into its perception and management. Infodemiology, which examines the distribution…
Abstract Number: 2192 • ACR Convergence 2025
Survey of Healthcare Providers’ Knowledge and Attitudes Toward the Management of Uncontrolled Gout
Shilpa Sharan¹, Clare Sonntag², Beth Miller¹, Kaitlyn Mayer¹ and Nissreen Elfadawy³, ¹The HWP Group, Upper Saddle River, NJ, ²The HWP Group, Upper Saddle River, ³University Hospitals, Geauga Medical Center, Chardon, OH
Background/Purpose: Although uncontrolled gout (UG) is an inflammatory arthritis triggered by crystallization of monosodium urate within joints following hyperuricemia, increasing evidence supports its classification as…
Abstract Number: 1995 • ACR Convergence 2025
The Prevalence of Multimorbidity and Polypharmacy Among US Adults with Gout: A General Population-Based Study
Chio Yokose¹, Natalie McCormick², Jiaqi Wang², Sharan Rai³, leo lu⁴ and Hyon K. Choi⁵, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Gout is an inflammatory-metabolic condition that is associated with a heavy burden of cardiovascular-kidney-metabolic (CKM) comorbidities. Accordingly, multimorbidity and polypharmacy are important considerations which…
Abstract Number: 1141 • ACR Convergence 2025
Modulation of Inflammatory Responses by Dental Pulp Stem Cell Extracellular Vesicles in Monosodium Urate-Stimulated Macrophages
Sadiq Umar¹, Kasey Leung² and Sriram Ravindran², ¹University of Illinois at Chicago, Chicago, IL, ²University of Illinois, Chicago, IL
Background/Purpose: Gout is the most prevalent form of inflammatory arthritis, with rising global incidence. It results from the deposition of monosodium urate (MSU) crystals in…
Abstract Number: 1012 • ACR Convergence 2025
Racial and Gender Disparities in Gout Clinical Trials
Fizza Zulfiqar¹, Dania Kaur², Meaghan Bethea³, Taylor Spencer⁴, Samhitha Bitla⁵, Abhinav Vyas⁶ and Camelia Arsene⁷, ¹Trinity Health Oakland/Wayne State University, Pontiac, MI, ²North Alabama Medical Center, Muscle Shoals, AL, ³Trinity Health Oakland Hopsital, Pontiac, MI, ⁴Trinity Health Oaklnd Hospital, Pontiac, MI, ⁵Trinity Health Oakland Hospital, Pontiac, MI, ⁶Vanderbilt University, Nashvile, TN, ⁷Trinity Health Oakland Hospital, Pontiac
Background/Purpose: To develop effective novel treatment strategies for Gout disease that cater to patients from diverse backgrounds, it is crucial that all racial groups, without…
Abstract Number: 2014 • ACR Convergence 2025
Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with eGFR < 60ml/min/1.73m2:A Post-Hoc Analysis of 24-Week Data
Yu Xue¹, Tianshu Chu², Jiankang Hu³, Wei Gou⁴, Ning Zhang⁵, Juan Li⁶, Jing Yu⁷, Rongping Li⁸, Rongbin Li⁹, Long Qian¹⁰, Xinwang Duan¹¹, Lihua Duan¹² and Hejian Zou¹, ¹Department of Rheumatology,Huashan Hospital, Fudan University, Shanghai, China, shanghai, China (People's Republic), ²Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, zhengzhou, China (People's Republic), ³Department of Rheumatology, Pingxiang People's Hospital, Pingxiang,China,, Pingxiang, China (People's Republic), ⁴Department of Rheumatology, Hebei Petro ChinaCentral Hospital, Langfang, China, Langfang, China (People's Republic), ⁵Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shengjing, China (People's Republic), ⁶The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), ⁷Department of Rheumatology, The FirstAffiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), ⁸Department of Rheumatology, The First Affiliated Hospital of GannanMedical University, Ganzhou, China, Ganzhou, China (People's Republic), ⁹Department ofRheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), ¹⁰Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), ¹¹The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ¹²Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)
Background/Purpose: Approximately 70% of adults with gout have CKD (Chronic Kidney Disease) ≥stage 3 (i.e estimated glomerular filtration rate (eGFR) < 60ml/min/1.73m2), significantly restricts treatment…
Abstract Number: 1993 • ACR Convergence 2025
Risk of Cardiovascular Conditions, Bone Fractures and Mortality in Patients with Uncontrolled Gout in Comparison to Those with Controlled Gout
Tingting Zhang¹, Christian W. Mende², Ashraf El-Meanawy³, Michael Pillinger⁴, Kaiding Zhu⁵, Bradley Marder⁶ and Brian Lamoreaux⁷, ¹Amgen, Inc., Thousand Oaks, ²University of California San Diego, San Diego, CA, ³Medical College of Wisconsin, Milwaukee, WI, ⁴New York University Grossman School of Medicine, New York,, NY, ⁵Amgen, Inc., San Francisco, CA, ⁶AMGEN, Inc, Denver, CO, ⁷Amgen, Inc., Deerfield, IL
Background/Purpose: Gout may increase the risk of cardiovascular events (CVEs) and bone fractures through urate deposition and chronic inflammation1,2. However, the additional effects of uncontrolled…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].